NCT01342198 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet


Sponsors: Pfizer	Phases: Phase I
Indications	Acronym:
Healthy
Age Groups: Adult	Gender: Both
Names: Drug: Pregabalin controlled release, 330 mg Drug: Pregabalin controlled release, 330 mg Drug: erythromycin	Enrollment: 18

Additional information about NCT01342198.